Pharmacy

The vaccines that could make a big impact on healthcare, from radical new flu vaccines to simplified meningococcal vaccine regimens.

From drug price concerns to the evolving role of PBMs to the influence of specialty pharmaceuticals, what healthcare executives think about the future of pharmacy.

How will payers, providers, and patients respond when a $2 million drug drops into the market?

In the first of many similar cases, the trial of Oklahoma versus Johnson & Johnson could frame who is to blame for the opioid epidemic.

With a more than $2 million price tag, how are payers going to deal with the recently approved Zolgensma?

Why hospital pharmacists are playing an increasingly-large role in patient care and why their involvement can boost medication outcomes and reduce errors.

Is real-world evidence up to the task of gaining new indications?

As pharmacies get deeper into chronic care treatment, what will it mean for both pharmacy and the world of managed care?

Here are five key metrics that executives should pay attention to as they navigate challenges.

The United States pays much higher drug prices than other countries. Could reference pricing be the fix?

Managed Healthcare Executive has identified 10 emerging industry leaders, working in the areas of pharmacy, health plans, health systems, and technology.

Drug costs are a hot political topic, but just how much do they disrupt healthcare?

Asembia offers broad coverage across specialty pharmacy.

Key ways healthcare executives can improve therapy compliance.

Pharmacists are in a unique position to improve orphan drug and precision medicine channels.

Experts offer their thoughts on what the specialty pharmacy industry will look like over the next year.

As the healthcare landscape continues to change at a rapid pace, drug manufacturers need to take a long, hard look at their marketing and commercialization options.

With so many new immunotherapy treatments on the horizon, pharmacists need to understand the ins and outs of immuno-oncology biomarkers to best serve their patients.

The FDA Commissioner says that insurers can help biosimilar adoption by taking short-term financial losses over long-term drug savings. What else should they be doing?

At the 2019 Asembia Specialty Pharmacy Summit, Cardinal Health’s Bruce Feinberg articulates the pros and cons of copay accumulator programs.

The present and bright future of cholesterol treatments.

Patients taking heart medications are most at risk when a pharmacy shuts its doors.

The real-world strategies used to manage the high cost of specialty meds.

The Trump Administration has taken a large interest in PBM drug rebates, which they say create higher drug prices. But do they?

The stakes have never been higher in reducing readmissions and hospitals are leveraging pharmacists’ expertise and putting them at the forefront of readmission reduction programs